Something changed in antibody discovery that the field spent a decade waiting for. Antibodies designed on a computer, rather than fished from an immunized animal or a display library, are now being validated in the lab at binding rates and affinities that hold their own against molecules found the traditional way. What was a promising research direction became, over the past two years, a working method, with computationally designed candidates advancing into clinical trials and major pharmaceutical companies signing partnerships measured in the hundreds of millions to get access to it.
The 6 Best AI Antibody Design Software Solutions in 2026
1. Converge Bio: Biology-Trained Models Across the Full Antibody Workflow
Converge Bio approaches antibody design with large language models trained not on text but on the languages of biology itself, DNA, RNA, protein, and chemical notations, so the system reasons in the medium the problem is actually written in. Its antibody platform spans the full workflow rather than a single step, supporting de novo design, affinity maturation, humanization, and developability assessment across multiple antibody formats, which addresses all four of the design problems in one place instead of leaving the later ones to the customer.
Two commitments distinguish it for teams that want to own their science. First, validation is defined by the wet lab, not the benchmark; the company measures itself by experimental confirmation and real program impact rather than in-silico scores, and reports antibodies with single-digit nanomolar binding where only a handful of candidates needed physical testing, against the far larger campaigns traditional optimization demands. Second, the customer keeps the intellectual property: teams can fine-tune private instances of the models on their own proprietary data while retaining full ownership of the molecules produced, which is a different proposition from handing a target to a partner and sharing in the result.
It is built to sit inside existing drug-development workflows, letting biologists get actionable outputs, optimized antibody candidates, humanized sequences, developability flags, without writing code or standing up infrastructure. Backed by a Series A led by Bessemer Venture Partners and used across programs with pharmaceutical and biotech partners, it fits organizations that want to accelerate their own antibody design while keeping both the data and the resulting IP firmly in-house.
2. Absci
Absci is one of the most visible names in AI antibody design, a public company that has published experimentally validated de novo results and built an integrated model-plus-lab operation. Its approach couples generative design with its own high-throughput wet-lab validation, so candidates are proposed and tested within one system rather than across vendors.
That integrated compute-and-lab model is its defining strength, valuable for teams that want design and initial validation from a single provider. Absci also operates as a drug-creation company with its own pipeline and pharma partnerships, so a prospective user should be clear about the engagement model, whether they are licensing design capability or entering a collaboration, since that shapes how the resulting molecules and their ownership are handled.
3. Generate Biomedicines
Generate Biomedicines is a leader in generative protein and antibody design, known for its programmable generative model and for advancing computationally designed antibodies into clinical trials, including candidates in infectious disease and immunology. Its science is among the most validated in the field, with an internal pipeline and large multi-target collaborations with major pharmaceutical companies.
Its strength is frontier de novo generation backed by demonstrated clinical progress, which places it at the leading edge of what generative design has achieved. It operates primarily as a therapeutics company advancing its own and partnered programs, so organizations engage it largely through collaboration rather than as self-service design software, a model suited to partnership-minded pharma rather than teams wanting to run design in-house and keep every molecule.
4. Cradle
Cradle offers an AI protein engineering platform used by teams at large pharmaceutical and industrial biotech organizations to co-optimize multiple protein properties at once, and it applies to antibodies as part of that broader protein-design remit. It is designed as software a team uses to improve its own molecules, with a focus on lead optimization and multi-property design.
For teams that already have a lead and need to optimize it across several attributes simultaneously, affinity, stability, expression, Cradle is a strong, self-service fit that keeps the work and the molecule with the customer. Its center of gravity is optimization of existing candidates and protein engineering broadly; teams whose primary need is antibody-specific de novo generation from a target should confirm how deeply its antibody generation reaches versus its optimization strengths.
5. BigHat Biosciences
BigHat Biosciences pairs machine learning with a synthetic-biology wet lab in a platform built to design and optimize therapeutic antibodies against multiple parameters at once, including function and developability. Its closed-loop model, design, build, test, learn, is aimed squarely at engineering antibodies that are not just potent but manufacturable and drug-like.
That emphasis on developability alongside binding is genuinely useful, since developability failures are a common and costly late-stage problem. BigHat works extensively through pharma collaborations, including named partnerships with large drugmakers, so teams evaluating it should understand the engagement as a partnership between its platform and their biologics program rather than purely licensed software, and weigh how that structure fits their IP and workflow preferences.
6. Prescient Design (Genentech)
Prescient Design, part of Genentech within the Roche group, builds generative antibody design technology anchored in one of the industry’s deepest reservoirs of biologics expertise and data. Its work integrates generative models with structure-based reasoning and large-scale experimental capability, representing the in-house AI antibody effort of a major pharmaceutical organization.
Its strength is the combination of frontier method development with the resources and validation infrastructure of a leading biologics company. Because it sits inside Genentech, it is less an openly available design tool a external team adopts and more the internal and collaborative engine of a specific pharma ecosystem, so its relevance depends on whether an organization is positioned to work within or alongside that environment rather than licensing standalone software.
Frequently Asked Questions
What is AI antibody design software?
AI antibody design software uses machine learning, including generative models and protein language models, to design, optimize, and assess therapeutic antibodies computationally. Rather than screening large physical libraries, it proposes candidate sequences predicted to bind a target and meet drug-like criteria, which are then validated in the lab. The strongest tools address several stages, from generating novel binders to optimizing affinity and checking developability.
How does AI antibody design differ from traditional discovery?
Traditional antibody discovery relies on immunizing animals or screening large display libraries to find binders, then optimizing them through many wet-lab rounds. AI design generates and refines candidates computationally first, so far fewer molecules need physical testing. This can compress timelines and reduce experimental burden, though laboratory validation remains essential, since a computational prediction is a hypothesis until candidates are synthesized and confirmed.
What does developability mean, and why does it matter?
Developability refers to the properties that determine whether an antibody can become a manufacturable, safe drug, including stability, solubility, expression yield, and low immunogenicity. A candidate can bind its target perfectly and still fail on developability, often late and expensively. AI tools that assess and engineer for developability alongside binding help teams avoid advancing molecules that look promising but cannot survive development.
Do companies keep ownership of AI-designed antibodies?
It depends entirely on the model. Some solutions are platforms a team runs itself, retaining full ownership of the molecules and often fine-tuning on private data they continue to own. Others are collaborations with AI-driven biotechs, where the resulting molecule’s economics may be shared or retained by the provider. Clarifying the ownership and engagement structure before starting is essential, since it shapes pipeline control and value capture.
What is the difference between in-silico and wet-lab validation?
In-silico validation means a model’s predictions match computational data or known structures, a useful signal but still a prediction. Wet-lab validation means designed candidates were physically made and tested, and performed as intended. Because many computationally strong candidates fail experimentally, wet-lab confirmation is the more meaningful evidence. Buyers should ask what fraction of designs were experimentally validated and at what binding affinities.
How should a team choose an AI antibody design solution?
Start with which design problems matter most, de novo generation, affinity maturation, structure prediction, or developability, since tools differ in coverage. Then decide whether you want software you operate and own, or a co-development partnership. Finally, weigh the strength of wet-lab validation over benchmark claims. Matching those three factors to your program is more useful than comparing feature lists alone.
